Market Overview

Egalet Tells Benzinga 'We Don't Have Any Idea Of Timing' Related To FDA Decision On ARYMO ER; BZ Note: Notable Analyst Tells Benzinga Typical Delay-To-Approval On Opiods Runs 2-4 Weeks


Latest Ratings for EGLT

Jan 2018Stifel NicolausDowngradesBuyHold
Nov 2017Gabelli & Co.DowngradesBuyHold
Jul 2017JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for EGLT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News FDA Exclusives Analyst Ratings General


Related Articles (EGLT)